Amgen is under slight
pressure after it modified investors on its oncology pipeline yesterday at the
International Myeloma Workshop in Boston.
It has employed a clinical hold on a premilinary study evaluating MCL-1
inhibitor AMG 397 in patients with multiple myeloma, NHL or AML due to a signal
of cardiac toxicity. To avoid further problems, it also halted its Phase 1
study of MCL-1 inhibitor AMG 176 in AML patients.
DATE
|
12-SEPTEMBER-2019
|
||
PREV. CLOSE
|
195.84
|
Volume
|
4,448,001
|
OPEN
|
196.83
|
Average Volume (3m)
|
3,122,306
|
HIGH
|
196.83
|
P/E Ratio
|
15.36
|
LOW
|
193.90
|
EPS
|
12.63
|
CLOSE
|
194.00
|
Recommendation: “Amgen slips on clinical
hold on early-stage” and hence, traders
may go for a SHORT-TRADE till it bounces back
from it’s over-sold region or hits the stop-loss. Traders are advised to
maintain trailing stop-loss and take profits.
Trade Table:
|
Date
|
LTP
|
Stop Loss
|
Support 1
|
Support 2
|
Support 3
|
|
12-SEPT-2019
|
194.00
|
196.80
|
192.95
|
191.95
|
190.10
|
Do you want to see other stock recommendations and their reviews
and performance, please view Recent posts of Samsung Electronics Co Ltd DRC Pref – a Long-trade (Buy)
opportunity and Intuitive
Surgical Inc – a Long-trade (Buy) opportunity.
Get the live
technical charts for Amgen Inc stock to get
the updated data to decide when to buy this stock and sell. You can utilize
various indicators like Bollinger Bands, MACD, RSI, etc to enable you to have a
firm decision about this stock. In fact, the Live technical Charts can be used
to draw charts for any Stock.
0 Comments